# Urcosimod PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/urcosimod

> The FDA approved urcosimod, sponsored by OKYO Pharma Ltd (OKYO), on January 23, 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only, year only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### Is urcosimod FDA approved?

Yes. The FDA approved urcosimod, sponsored by OKYO Pharma Ltd (OKYO), on January 23, 2026. SEC prospectus (424B): "January 23, 2026, we announced that the FDA approved compassionate use of urcosimod (0.05%) for treatment of neuropathic corneal pain." [Calendar and source filings](https://sec-api.dev/pdufa/urcosimod)

Source: SEC prospectus (424B), accession 0001493152-26-006946, https://www.sec.gov/Archives/edgar/data/1849296/000149315226006946/form424b5.htm (retrieved 2026-11-12). Last confirmed 2026-02-17. Cite: https://sec-api.dev/pdufa/urcosimod#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | urcosimod |
| Codes | OK-101 |
| Sponsor | OKYO Pharma Ltd (OKYO) https://sec-api.dev/companies/okyo/catalysts |
| Indications | ded patients |
| Modality |  |
| FDA designations | fast track |

## Timeline

### June 6, 2023: trial start

- Status: completed. Date confidence: exact. Stage: 2.
- First seen 2025-07-18, last confirmed 2026-02-17.
- SEC prospectus (424B) (accession 0001493152-26-006946): "June 6, 2023, we announced that patients in the ongoing phase 2b trial began dosing in the randomized portion of the phase 2b, multi-center, double-masked, placebo-controlled trial of topical ocular urcosimod to treat DED, following the two-week placebo run-in period intended to minimize the placebo effect." https://www.sec.gov/Archives/edgar/data/1849296/000149315226006946/form424b5.htm
- SEC prospectus (424B) (accession 0001493152-26-006417): "June 6, 2023, we announced that patients in the ongoing phase 2b trial began dosing in the randomized portion of the phase 2b, multi-center, double-masked, placebo-controlled trial of topical ocular urcosimod to treat DED, following the two-week placebo run-in period intended to minimize the placebo effect." https://www.sec.gov/Archives/edgar/data/1849296/000149315226006417/form424b5.htm
- SEC prospectus (424B) (accession 0001493152-26-006039): "On June 6, 2023, we announced that patients in the ongoing phase 2b trial began dosing in the randomized portion of the phase 2b, multi-center, double-masked, placebo-controlled trial of topical ocular urcosimod to treat DED, following the two-week placebo run-in period intended to minimize the placebo effect." https://www.sec.gov/Archives/edgar/data/1849296/000149315226006039/form424b5.htm
- SEC prospectus (424B) (accession 0001493152-26-006039): "June 6, 2023, we announced that patients in the ongoing phase 2b trial began dosing in the randomized portion of the phase 2b, multi-center, double-masked, placebo-controlled trial of topical ocular urcosimod to treat DED, following the two-week placebo run-in period intended to minimize the placebo effect." https://www.sec.gov/Archives/edgar/data/1849296/000149315226006039/form424b5.htm
- SEC Form 10-K (accession 0001641172-25-020240): "June 6, 2023, we announced that patients in the ongoing phase 2b trial began dosing in the randomized portion of the phase 2b, multi-center, double-masked, placebo-controlled trial of topical ocular urcosimod to treat DED, following the two-week placebo run-in period intended to minimize the placebo effect." https://www.sec.gov/Archives/edgar/data/1849296/000164117225020240/form20-f.htm

### Jan 2024: topline data readout

- Status: completed, positive. Date confidence: month. Stage: 2. Indication: DED patients.
- First seen 2025-01-29, last confirmed 2025-01-29.
- Press release filed with the SEC (EX-99) (accession 0001493152-25-004156): "January of 2024, OKYO reported positive top line data from the Phase 2b trial of OK-101 to treat DED patients." https://www.sec.gov/Archives/edgar/data/1849296/000149315225004156/ex99-1.htm

### Q4 2025: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2.
- First seen 2025-01-29, last confirmed 2025-01-29.
- Press release filed with the SEC (EX-99) (accession 0001493152-25-004156): "Company anticipates completing enrollment of the 48-patient trial by the end of 2Q 2025 and releasing top-line data on the Phase 2a trial in 4Q 2025." https://www.sec.gov/Archives/edgar/data/1849296/000149315225004156/ex99-1.htm

### 2026: topline data readout

- Status: scheduled. Date confidence: year.
- First seen 2025-09-22, last confirmed 2026-01-30.
- Press release filed with the SEC (EX-99) (accession 0001493152-26-004550): "We anticipate topline results from this trial in 2026, with ongoing negotiations for clinical sites." https://www.sec.gov/Archives/edgar/data/1849296/000149315226004550/ex99-2.htm
- Press release filed with the SEC (EX-99) (accession 0001493152-25-014405): "Negotiations with several leading U.S. clinical sites are underway, and OKYO anticipates topline data from this trial in 2026." https://www.sec.gov/Archives/edgar/data/1849296/000149315225014405/ex99-1.htm

### January 23, 2026: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-02-11, last confirmed 2026-02-17.
- SEC prospectus (424B) (accession 0001493152-26-006946): "January 23, 2026, we announced that the FDA approved compassionate use of urcosimod (0.05%) for treatment of neuropathic corneal pain." https://www.sec.gov/Archives/edgar/data/1849296/000149315226006946/form424b5.htm
- SEC prospectus (424B) (accession 0001493152-26-006946): "January 23, 2026, we announced that the U.S. Food and Drug Administration (FDA) approved compassionate use of urcosimod (0.05%) for treatment of neuropathic corneal pain." https://www.sec.gov/Archives/edgar/data/1849296/000149315226006946/form424b5.htm
- SEC prospectus (424B) (accession 0001493152-26-006417): "January 23, 2026, we announced that the FDA approved compassionate use of urcosimod (0.05%) for treatment of neuropathic corneal pain." https://www.sec.gov/Archives/edgar/data/1849296/000149315226006417/form424b5.htm
- SEC prospectus (424B) (accession 0001493152-26-006417): "January 23, 2026, we announced that the U.S. Food and Drug Administration (FDA) approved compassionate use of urcosimod (0.05%) for treatment of neuropathic corneal pain." https://www.sec.gov/Archives/edgar/data/1849296/000149315226006417/form424b5.htm
- SEC prospectus (424B) (accession 0001493152-26-006039): "January 23, 2026, we announced that the U.S. Food and Drug Administration (FDA) approved compassionate use of urcosimod (0.05%) for treatment of neuropathic corneal pain." https://www.sec.gov/Archives/edgar/data/1849296/000149315226006039/form424b5.htm

### 2H 2026: trial start

- Status: scheduled. Date confidence: half. Stage: 3.
- First seen 2026-01-28, last confirmed 2026-09-29.
- Press release filed with the SEC (EX-99) (accession 0001493152-26-044760): "OKYO plans to initiate a global Phase 3 pivotal clinical trial in the second half of this year, enrolling approximately 111 patients to evaluate a single-dose regimen of urcosimod for the treatment of NCP." https://www.sec.gov/Archives/edgar/data/1849296/000149315226044760/ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001493152-26-041864): "OKYO plans to initiate a global Phase 3 pivotal clinical trial in the second half of this year, enrolling approximately 111 patients to evaluate a single-dose regimen of urcosimod for the treatment of NCP." https://www.sec.gov/Archives/edgar/data/1849296/000149315226041864/ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001493152-26-034927): "OKYO plans to initiate a global Phase 3 pivotal clinical trial in the second half of this year, enrolling approximately 111 patients to evaluate a single-dose regimen of urcosimod for the treatment of NCP." https://www.sec.gov/Archives/edgar/data/1849296/000149315226034927/ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001493152-26-034686): "OKYO plans to initiate a global Phase 3 pivotal clinical trial in the second half of this year, enrolling approximately 111 patients to evaluate a single-dose regimen of urcosimod for the treatment of NCP." https://www.sec.gov/Archives/edgar/data/1849296/000149315226034686/ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001493152-26-034316): "OKYO plans to initiate a global Phase 3 pivotal clinical trial in the second half of this year, enrolling approximately 111 patients to evaluate a single-dose regimen of urcosimod for the treatment of NCP." https://www.sec.gov/Archives/edgar/data/1849296/000149315226034316/ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001493152-26-034362): "OKYO plans to initiate a global Phase 3 pivotal clinical trial in the second half of this year, enrolling approximately 111 patients to evaluate a single-dose regimen of urcosimod for the treatment of NCP." https://www.sec.gov/Archives/edgar/data/1849296/000149315226034362/ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001493152-26-034160): "OKYO plans to initiate a global Phase 3 pivotal clinical trial in the second half of this year, enrolling approximately 111 patients to evaluate a single-dose regimen of urcosimod for the treatment of NCP." https://www.sec.gov/Archives/edgar/data/1849296/000149315226034160/ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001493152-26-034197): "OKYO plans to initiate a global Phase 3 pivotal clinical trial in the second half of this year, enrolling approximately 111 patients to evaluate a single-dose regimen of urcosimod for the treatment of NCP." https://www.sec.gov/Archives/edgar/data/1849296/000149315226034197/ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001493152-26-034201): "OKYO plans to initiate a global Phase 3 pivotal clinical trial in the second half of this year, enrolling approximately 111 patients to evaluate a single-dose regimen of urcosimod for the treatment of NCP." https://www.sec.gov/Archives/edgar/data/1849296/000149315226034201/ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001493152-26-033991): "OKYO plans to initiate a global Phase 3 pivotal clinical trial in the second half of this year, enrolling approximately 111 patients to evaluate a single-dose regimen of urcosimod for the treatment of NCP." https://www.sec.gov/Archives/edgar/data/1849296/000149315226033991/ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001493152-26-034019): "OKYO plans to initiate a global Phase 3 pivotal clinical trial in the second half of this year, enrolling approximately 111 patients to evaluate a single-dose regimen of urcosimod for the treatment of NCP." https://www.sec.gov/Archives/edgar/data/1849296/000149315226034019/ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001493152-26-033850): "OKYO plans to initiate a global Phase 3 pivotal clinical trial in the second half of this year, enrolling approximately 111 patients to evaluate a single-dose regimen of urcosimod for the treatment of NCP." https://www.sec.gov/Archives/edgar/data/1849296/000149315226033850/ex99-1.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/urcosimod.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Urcosimod PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/urcosimod

```bibtex
@misc{secapidev_pdufa_urcosimod_20261116,
  title        = {Urcosimod PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/urcosimod}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_urcosimod_20261116","title":"Urcosimod PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/urcosimod","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
